Pharmacokinetics of Antituberculosis Agents in HIV-Infected Persons With Tuberculosis
Patients receive up to 8 weeks of two or more anti-tuberculosis drugs, of which at least two
are isoniazid, rifampin, pyrazinamide, or ethambutol. Blood specimens are collected at 2, 6,
and 10 hours after administration of study medication, once between Days 10 and 14 of a
phase of daily treatment and once while on an intermittent dose regimen (twice weekly or
three times weekly).
Interventional
Primary Purpose: Treatment
Keith Chirgwin
Study Chair
United States: Federal Government
ACTG 309
NCT00000950
Name | Location |
---|---|
Harbor UCLA Med Ctr | Torrance, California 90502 |
Tulane Univ School of Medicine | New Orleans, Louisiana 70112 |
Mount Sinai Med Ctr | New York, New York 10029 |
Univ of Southern California / LA County USC Med Ctr | Los Angeles, California 900331079 |
Beth Israel Med Ctr | New York, New York 10003 |
Univ of Pennsylvania at Philadelphia | Philadelphia, Pennsylvania 19104 |
Univ of Hawaii | Honolulu, Hawaii 96816 |
SUNY / Health Sciences Ctr at Brooklyn | Brooklyn, New York 112032098 |
MetroHealth Med Ctr | Cleveland, Ohio 441091998 |
Queens Med Ctr | Honolulu, Hawaii 96816 |
Emory Univ | Atlanta, Georgia 30308 |
St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr | New York, New York 10021 |
University of Miami (Pediatric) | Miami, Florida 33136 |